The role of PET/CT in cervical cancer

Frontiers in Oncology

Volumn 3 FEB, Issue , 2013, Pages

  Herrera, Fernanda G ^a   Prior, John O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cervical cancer; Fluorodeoxyglucose F18; Planning treatment volumes; Positron emission tomography; Radiation therapy

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CILENGITIDE; CISPLATIN; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 60; DIACETYL DI(N4 METHYLTHIOSEMICARBAZONE) CU 64; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; NODAGA RGD GA 68; TRACER; UNCLASSIFIED DRUG;

ANGIOGENESIS; BRACHYTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG WITHDRAWAL; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HUMAN; HYPOXIA; LYMPH NODE METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; RADIATION DOSE; REVIEW; SENSITIVITY AND SPECIFICITY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UTERINE CERVIX CANCER;

EID: 84890778355     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00034     Document Type: Review

References (88)

1. Alva, A., Slovin, S., Daignault, S., Carducci, M., Dipaola, R., Pienta, K., et al. (2012). Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest. New Drugs 30, 749-757.
2. Avraamides, C. J., Garmy-Susini, B., and Varner, J. A. (2008). Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 8, 604-617.
3. Bachtiary, B., Dewitt, A., Pintilie, M., Jezioranski, J., Ahonen, S., Levin, W., et al. (2005). Comparison of late toxicity between continuous low-dose-rate and pulsed-dose-rate brachytherapy in cervical cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 63, 1077-1082.
4. Beekman, K. W., Colevas, A. D., Cooney, K., Dipaola, R., Dunn, R. L., Gross, M., et al. (2006). Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin. Genitourin. Cancer 4, 299-302.
5. Blower, P. J., Lewis, J. S., and Zweit, J. (1996). Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl. Med. Biol. 23, 957-980.
6. Bodurka-Bevers, D., Morris, M., Eifel, P. J., Levenback, C., Bevers, M. W., Lucas, K. R., et al. (2000). Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol. Oncol. 78, 187-193.
7. Boughanim, M., Leboulleux, S., Rey, A., Pham, C. T., Zafrani, Y., Duvillard, P., et al. (2008). Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J. Clin. Oncol. 26, 2558-2561.
8. Brooks, P. C., Clark, R. A., and Cheresh, D. A. (1994a). Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264, 569-571.
9. Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., et al. (1994b). Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164.
10. Brooks, R. A., Rader, J. S., Dehdashti, F., Mutch, D. G., Powell, M. A., Thaker, P. H., et al. (2009). Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol. Oncol. 112, 104-109.
11. Brown, J. M., and Giaccia, A. J. (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416.
12. Buchegger, F., Viertl, D., Baechler, S., Dunet, V., Kosinski, M., Poitry-Yamate, C., et al. (2011). 68Ga-NODAGA-RGDyK for alphavbeta3 integrin PET imaging. Preclinical investigation and dosimetry. Nuklearmedizin 50, 225-233.
13. Chan, P., Dinniwell, R., Haider, M. A., Cho, Y. B., Jaffray, D., Lockwood, G., et al. (2008). Inter-and intrafractional tumor and organ movement in patients with cervical cancer undergoing radiotherapy: a cinematic-MRI point-of-interest study. Int. J. Radiat. Oncol. Biol. Phys. 70, 1507-1515.
14. Choi, C. W., Cho, C. K., Yoo, S. Y., Kim, M. S., Yang, K. M., Yoo, H. J., et al. (2009). Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int. J. Radiat. Oncol. Biol. Phys. 74, 147-153.
15. Chou, H. H., Chang, T. C., Yen, T. C., Ng, K. K., Hsueh, S., Ma, S. Y., et al. (2006). Low value of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in primary staging of early-stage cervical cancer before radical hysterectomy. J. Clin. Oncol. 24, 123-128.
16. Daisne, J. F., Sibomana, M., Bol, A., Doumont, T., Lonneux, M., and Gregoire, V. (2003). Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother. Oncol. 69, 247-250.
17. Dechantsreiter, M. A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., et al. (1999). N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J. Med. Chem. 42, 3033-3040.
18. Dehdashti, F., Grigsby, P. W., Lewis, J. S., Laforest, R., Siegel, B. A., and Welch, M. J. (2008). Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J. Nucl. Med. 49, 201-205.
19. Dehdashti, F., Grigsby, P. W., Mintun, M. A., Lewis, J. S., Siegel, B. A., and Welch, M. J. (2003). Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 55, 1233-1238.
20. Duenas-Gonzalez, A., Zarba, J. J., Patel, F., Alcedo, J. C., Beslija, S., Casanova, L., et al. (2011). Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J. Clin. Oncol. 29, 1678-1685.
21. Eifel, P. J., Morris, M., Wharton, J. T., and Oswald, M. J. (1994). The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int. J. Radiat. Oncol. Biol. Phys. 29, 9-16.
22. Elit, L., Fyles, A. W., Oliver, T. K., Devries-Aboud, M. C., Fung-Kee-Fung, M., and Members of the Gynecology Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based, C. (2010). Follow-up for women after treatment for cervical cancer. Curr. Oncol. 17, 65-69.
23. Esthappan, J., Mutic, S., Malyapa, R. S., Grigsby, P. W., Zoberi, I., Dehdashti, F., et al. (2004). Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int. J. Radiat. Oncol. Biol. Phys. 58, 1289-1297.
24. Ferlay, J., Parkin, D. M., and Steliarova-Foucher, E. (2010a). Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46, 765-781.
25. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. (2010b). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917.
26. Friess, H., Langrehr, J. M., Oettle, H., Raedle, J., Niedergethmann, M., Dittrich, C., et al. (2006). A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6:285. doi: 10.1186/1471-2407-6-285
27. Fyles, A., Milosevic, M., Hedley, D., Pintilie, M., Levin, W., Manchul, L., et al. (2002). Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol. 20, 680-687.
28. Fyles, A., Milosevic, M., Pintilie, M., Syed, A., Levin, W., Manchul, L., et al. (2006). Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother. Oncol. 80, 132-137.
29. Fyles, A. W., Pintilie, M., Kirkbride, P., Levin, W., Manchul, L. A., and Rawlings, G. A. (1995). Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis. Radiother. Oncol. 35, 107-117.
30. Gaffney, D., Mundt, A., Schwarz, J., and Eifel, P. (2012). Advances in clinical research in gynecologic radiation oncology: an RTOG symposium. Int. J. Gynecol. Cancer 22, 667-674.
31. Gaffney, D. K. (2005). A phase I-II study of COX-2 inhibitor celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int. J. Radiat. Oncol. Biol. Phys. S93.
32. Green, J. A., Kirwan, J. M., Tierney, J. F., Symonds, P., Fresco, L., Collingwood, M., et al. (2001). Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358, 781-786.
33. Grigsby, P. W., Malyapa, R. S., Higashikubo, R., Schwarz, J. K., Welch, M. J., Huettner, P. C., et al. (2007). Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix. Mol. Imaging Biol. 9, 278-283.
34. Grigsby, P. W., Siegel, B. A., and Dehdashti, F. (2001). Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J. Clin. Oncol. 19, 3745-3749.
35. Grigsby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J., and Zoberi, I. (2004). Lymph node control in cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 59, 706-712.
36. Gruber, G., Hess, J., Stiefel, C., Aebersold, D. M., Zimmer, Y., Greiner, R. H., et al. (2005). Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapy. Br. J. Cancer 92, 41-46.
37. Haie-Meder, C., Potter, R., Van Limbergen, E., Briot, E., De Brabandere, M., Dimopoulos, J., et al. (2005). Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother. Oncol. 74, 235-245.
38. Hazelbag, S., Kenter, G. G., Gorter, A., Dreef, E. J., Koopman, L. A., Violette, S. M., et al. (2007). Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 212, 316-324.
39. Herrera, F. G., Chan, P., Doll, C., Milosevic, M., Oza, A., Syed, A., et al. (2006). A prospective phase I/II trial of the cycloxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor micro environment. Int. J. Radiat. Oncol. Biol. Phys. 67, 97-103.
40. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P. (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56, 4509-4515.
41. Hockel, M., Schlenger, K., Hockel, S., and Vaupel, P. (1999). Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59, 4525-4528.
42. Kidd, E. A., Siegel, B. A., Dehdashti, F., and Grigsby, P. W. (2007). The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110, 1738-1744.
43. Kidd, E. A., Siegel, B. A., Dehdashti, F., Rader, J. S., Mutch, D. G., Powell, M. A., et al. (2010a). Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J. Clin. Oncol. 28, 2108-2113.
44. Kidd, E. A., Siegel, B. A., Dehdashti, F., Rader, J. S., Mutic, S., Mutch, D. G., et al. (2010b). Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 77, 1085-1091.
45. Kidd, E. A., Spencer, C. R., Huettner, P. C., Siegel, B. A., Dehdashti, F., Rader, J. S., et al. (2009). Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer 115, 3548-3554.
46. Kunos, C., Brindle, J. M., and Debernardo, R. (2012a). Stereotactic radiosurgery for gynecologic cancer. J. Vis. Exp. pii: 3793.
47. Kunos, C. A., Debernardo, R., Radivoyevitch, T., Fabien, J., Dobbins, D. C., Zhang, Y., et al. (2012b). Hematological toxicity after robotic stereotactic body radiosurgery for treatment of metastatic gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 84, e35-e41.
48. Lagasse, L. D., Creasman, W. T., Shingleton, H. M., Ford, J. H., and Blessing, J. A. (1980). Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. Gynecol. Oncol. 9, 90-98.
49. Lewis, J. S., Laforest, R., Dehdashti, F., Grigsby, P. W., Welch, M. J., and Siegel, B. A. (2008). An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J. Nucl. Med. 49, 1177-1182.
50. Liang, Y., Bydder, M., Yashar, C. M., Rose, B. S., Cornell, M., Hoh, C. K., et al. (2012). Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 85, 406-414.
51. Lin, L. L., Mutic, S., Low, D. A., Laforest, R., Vicic, M., Zoberi, I., et al. (2007). Adaptive brachytherapy treatment planning for cervical cancer using FDG-PET. Int. J. Radiat. Oncol. Biol. Phys. 67, 91-96.
52. Lin, L. L., Yang, Z., Mutic, S., Miller, T. R., and Grigsby, P. W. (2006). FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. Int. J. Radiat. Oncol. Biol. Phys. 65, 177-181.
53. Lyng, H., Sundfor, K., and Rofstad, E. K. (2000). Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis. Int. J. Radiat. Oncol. Biol. Phys. 46, 935-946.
54. Ma, D. J., Zhu, J. M., and Grigsby, P. W. (2011). Tumor volume discrepancies between FDG-PET and MRI for cervical cancer. Radiother. Oncol. 98, 139-142.
55. Malyapa, R., Mutic, S., Low, D. A., Zoberi, I., Bosch, W. R., Laforest, R., et al. (2002). Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 54, 1140-1146.
56. Maurer, G. D., Tritschler, I., Adams, B., Tabatabai, G., Wick, W., Stupp, R., et al. (2009). Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro. Oncol. 11, 747-756.
57. Mayr, N. A., Taoka, T., Yuh, W. T., Denning, L. M., Zhen, W. K., Paulino, A. C., et al. (2002). Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 52, 14-22.
58. Mell, L. K., Kochanski, J. D., Roeske, J. C., Haslam, J. J., Mehta, N., Yamada, S. D., et al. (2006). Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 66, 1356-1365.
59. Metser, U., Golan, O., Levine, C. D., and Even-Sapir, E. (2005). Tumor lesion detection: when is integrated positron emission tomography/computed tomography more accurate than side-by-side interpretation of positron emission tomography and computed tomography? J. Comput. Assist. Tomogr. 29, 554-559.
60. Milosevic, M., Fyles, A., Hedley, D., and Hill, R. (2004). The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin. Radiat. Oncol. 14, 249-258.
61. Mittra, E., El-Maghraby, T., Rodriguez, C. A., Quon, A., Mcdougall, I. R., Gambhir, S. S., et al. (2009). Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma. Eur. J. Nucl. Med. Mol. Imaging 36, 1952-1959.
62. Nam, H., Huh, S. J., Ju, S. G., Park, W., Lee, J. E., Choi, J. Y., et al. (2012). 18F-fluorodeoxyglucose positron emisson tomography/computed tomography guided conformal brachytherapy for cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 84, e29-e34.
63. Narayan, K., Hicks, R. J., Jobling, T., Bernshaw, D., and Mckenzie, A. F. (2001). A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment. Int. J. Gynecol. Cancer 11, 263-271.
64. Pecorelli, S., Zigliani, L., and Odicino, F. (2009). Revised FIGO staging for carcinoma of the cervix. Int. J. Gynaecol. Obstet. 105, 107-108.
65. Perez, C. A., Grigsby, P. W., Chao, K. S., Mutch, D. G., and Lockett, M. A. (1998). Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int. J. Radiat. Oncol. Biol. Phys. 41, 307-317.
66. Potter, R., Haie-Meder, C., Van Limbergen, E., Barillot, I., De Brabandere, M., Dimopoulos, J., et al. (2006). Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother. Oncol. 78, 67-77.
67. Rasey, J. S., Grunbaum, Z., Magee, S., Nelson, N. J., Olive, P. L., Durand, R. E., et al. (1987). Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat. Res. 111, 292-304.
68. Rasey, J. S., Koh, W. J., Grierson, J. R., Grunbaum, Z., and Krohn, K. A. (1989). Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 17, 985-991.
69. Reardon, D. A., Fink, K. L., Mikkelsen, T., Cloughesy, T. F., O'neill, A., Plotkin, S., et al. (2008a). Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26, 5610-5617.
70. Reardon, D. A., Nabors, L. B., Stupp, R., and Mikkelsen, T. (2008b). Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin. Investig. Drugs 17, 1225-1235.
71. Reardon, D. A., Neyns, B., Weller, M., Tonn, J. C., Nabors, L. B., and Stupp, R. (2011). Cilengitide: an RGD pentapeptide alphanubeta3 and alphanubeta5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 7, 339-354.
72. Reinhardt, M. J., Ehritt-Braun, C., Vogelgesang, D., Ihling, C., Hogerle, S., Mix, M., et al. (2001). Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 218, 776-782.
73. Roh, J. W., Seo, S. S., Lee, S., Kang, K. W., Kim, S. K., Sim, J. S., et al. (2005). Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: a prospective surgicopathologic correlation study. Eur. J. Cancer 41, 2086-2092.
74. Rose, B. S., Liang, Y., Lau, S. K., Jensen, L. G., Yashar, C. M., Hoh, C. K., et al. (2012). Correlation between radiation dose to (1)(8)F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 83, 1185-1191.
75. Rose, P. G., Adler, L. P., Rodriguez, M., Faulhaber, P. F., Abdul-Karim, F. W., and Miraldi, F. (1999). Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J. Clin. Oncol. 17, 41-45.
76. Schefter, T. E., Winter, K., Kwon, J. S., Stuhr, K., Balaraj, K., Yaremko, B. P., et al. (2012). A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int. J. Radiat. Oncol. Biol. Phys. 83, 1179-1184.
77. Schuetz, M., Schmid, M. P., Potter, R., Kommata, S., Georg, D., Lukic, D., et al. (2010). Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol. 49, 941-947.
78. Schwarz, J. K., Siegel, B. A., Dehdashti, F., and Grigsby, P. W. (2007). Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 298, 2289-2295.
79. Sironi, S., Buda, A., Picchio, M., Perego, P., Moreni, R., Pellegrino, A., et al. (2006). Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology 238, 272-279.
80. Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U., Clement, P. M., et al. (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 2712-2718.
81. Sugawara, Y., Eisbruch, A., Kosuda, S., Recker, B. E., Kison, P. V., and Wahl, R. L. (1999). Evaluation of FDG PET in patients with cervical cancer. J. Nucl. Med. 40, 1125-1131.
82. Townsley, C. A., Milosevic, M., Haider, M. A., Mackay, H., Yeung, I., Kim, S., et al. (2011). A phase I/II study of cisplatin and radiation in combination with sorafenib in cervical cancer: evaluation of biomarkers. J. Clin. Oncol. 29.
83. Tsai, C. S., Chang, T. C., Lai, C. H., Tsai, C. C., Ng, K. K., Hsueh, S., et al. (2004). Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT. Int. J. Radiat. Oncol. Biol. Phys. 58, 1506-1512.
84. Vale, C., Nightingale, A., Spera, N., Whelan, A., Hanley, B., and Tierney, J. F. (2010). Late complications from chemoradiotherapy for cervical cancer: reflections from cervical cancer survivors 10 years after the national cancer institute alert. Clin. Oncol. (R Coll Radiol) 22, 588-589.
85. Varia, M. A., Bundy, B. N., Deppe, G., Mannel, R., Averette, H. E., Rose, P. G., et al. (1998). Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int. J. Radiat. Oncol. Biol. Phys. 42, 1015-1023.
86. Vermorken, J. B., Guigay, J., Mesia, R., Trigo, J. M., Keilholz, U., Kerber, A., et al. (2011). Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br. J. Cancer 104, 1691-1696.
87. Wong, T. Z., Jones, E. L., and Coleman, R. E. (2004). Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol. Imaging Biol. 6, 55-62.
88. Wright, J. D., Dehdashti, F., Herzog, T. J., Mutch, D. G., Huettner, P. C., Rader, J. S., et al. (2005). Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer 104, 2484-2491.